Now Published: OCEANIC-STROKE Shows Asundexian Prevents Recurrent Stroke Without Added Bleeding

Now Published: OCEANIC-STROKE Shows Asundexian Prevents Recurrent Stroke Without Added Bleeding

April 23, 2026

When the results from the OCEANIC-STROKE trial were released in late 2025, showing that the investigational FXIa inhibitor asundexian significantly reduced recurrent stroke risk without increasing major bleeding, it wasn’t just a footnote in a medical journal—it was a potential turning point for stroke prevention strategies nationwide. For communities like ours here in Seattle, where the prevalence of cardiovascular risk factors aligns closely with national averages and where institutions like the University of Washington Medicine and Harborview Medical Center are deeply embedded in both clinical care and neurological research, this development carries tangible local relevance. The trial, which enrolled over 12,000 patients across multiple countries between January 2023 and February 2025, demonstrated that asundexian, when added to standard antiplatelet therapy, lowered the risk of ischemic stroke in high-risk individuals who had recently experienced a stroke or transient ischemic attack (TIA). What stood out wasn’t just the efficacy signal—it was the safety profile: no significant increase in major bleeding events compared to placebo, a critical consideration given that bleeding risk has long limited the use of more potent antithrombotics in secondary stroke prevention.

Digging into the trial’s design, as detailed in the European Stroke Journal publication from January 2026 and corroborated by ClinicalTrials.gov record NCT05686070, reveals a rigorously structured, placebo-controlled, double-blind study. Participants were enrolled within 72 hours of an index stroke (NIHSS ≤ 15) or high-risk TIA (ABCD2 score ≥6), with inclusion requiring evidence of atherosclerosis—either through imaging of extra- or intracranial vessels, a documented history of atherosclerotic disease, or an acute non-lacunar infarct on imaging. Exclusions were carefully applied to avoid confounding factors: cardioembolic stroke sources requiring anticoagulation were ruled out, as were active non-trivial bleeding events beyond minor hemorrhagic infarction. Stratification by planned antiplatelet regimen—single versus dual therapy—ensured balance, with 63% of participants slated for dual antiplatelets as standard initial care. Baseline characteristics showed a cohort that was 67% male, with a mean age of 68 years (standard deviation 11), and ischemic stroke as the index event in 95% of cases. TOAST classification revealed a diverse etiology: 43% large artery atherosclerosis, 22% small vessel disease, 30% undetermined, and only 2% cardioembolic—underscoring the trial’s focus on non-cardioembolic pathways where antiplatelets dominate and where FXIa inhibition might offer additive benefit without overlapping mechanisms.

The implications ripple outward, especially when viewed through a regional lens. In King County, where public health data from Seattle & King County Public Health consistently identifies stroke as a leading cause of long-term disability and where initiatives like the Washington State Coverdell Stroke Program work to improve systems of care from EMS transport to rehabilitation, any advancement that reduces recurrence without trading off safety warrants close attention. Harborview’s Comprehensive Stroke Center, certified by DNV GL and recognized as a state-designated Level 1 stroke facility, regularly participates in national trials and serves as a referral hub for complex cerebrovascular cases across the Pacific Northwest. Similarly, the University of Washington’s Department of Neurology, particularly through its Stroke Research Program, has contributed to prior FXI-related studies and maintains active collaborations with industry partners investigating novel antithrombotics. These institutions aren’t just passive observers—they’re active nodes in the translation of trial findings like OCEANIC-STROKE into real-world clinical conversations, especially as guideline committees begin to reassess secondary prevention paradigms in light of FXIa inhibition’s emerging role.

Of course, translating trial results into community impact isn’t automatic. It requires local infrastructure—clinicians who can interpret nuanced risk-benefit profiles, pharmacists equipped to manage medication access and adherence, and support systems that help patients navigate lifestyle modifications alongside pharmacotherapy. Given my background in biomedical sciences and public health communication, if this trend impacts you in the Seattle area, here are the three types of local professionals you need to know about:

  • Preventive Neurology Specialists: Look for physicians board-certified in neurology with additional fellowship training or focused practice in cerebrovascular disease and stroke prevention. They should be affiliated with accredited stroke centers (like those at Harborview, UW Medicine, or Swedish Cherry Hill) and demonstrate familiarity with emerging antithrombotic strategies beyond aspirin and clopidogrel—including ongoing trials involving FXIa inhibitors. Question about their approach to personalized risk assessment using imaging biomarkers and genetic factors when relevant.
  • Clinical Pharmacists with Anticoagulation Expertise: Seek practitioners embedded in ambulatory care clinics or integrated health systems (such as Kaiser Permanente Washington or Virginia Mason Franciscan Health) who specialize in managing antithrombotic therapies. Ideal candidates will have experience navigating insurance pathways for novel agents, monitoring for subtle bleeding signs (even if trial data suggests low risk), and coordinating with neurologists and primary care providers during transitions of care post-stroke or TIA.
  • Stroke Rehabilitation Coordinators: These professionals—often nurses or therapists with certified stroke rehabilitation credentials (CSRN or similar)—bridge acute care and long-term recovery. They should be connected to outpatient rehab programs at facilities like Northwest Hospital or Encompass Health Rehabilitation Hospital of Tacoma, and skilled at integrating secondary prevention education into therapy plans, ensuring patients understand medication purpose, adherence importance, and lifestyle synergies (blood pressure control, smoking cessation, diet) that complement pharmacologic intervention.

Ready to locate trusted professionals? Browse our complete directory of top-rated experts in the Seattle area today.